Targeting T cells with ustekinumab is a potential therapeutic strategy for AAV-GN that merits additional evaluation in clinical trials. To further clarify and define the role of specific T-cell ...
BOSTON--(BUSINESS WIRE)--Asimov, the synthetic biology company advancing the design and production of therapeutics, today announced the launch of the AAV Edge System, a comprehensive suite of tools ...
Adeno-associated viruses (AAVs) are used in nearly a dozen FDA-approved therapies and more than 900 R&D projects to deliver therapeutic payloads to cells. Yet, large-scale AAV production is still a ...
Asimov launched its AAV Edge Stable Producer system with the goal of addressing the shortcomings of traditional transient transfection-based production and bringing AAV manufacturing standards closer ...
Efficient viral vector production is essential for the cost-effective manufacture of cell and gene therapies. Many of the current production workflows are reliant on basal media in batch-mode, which ...
WALTHAM, Mass., April 22, 2024 /PRNewswire/ -- Affinia Therapeutics ("Affinia"), an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results